Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDGeneDx Holdings Corp. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | $0.06 | $0.06 | $0.06 |
| Q2 2025 | 1 | $0.11 | $0.12 | $0.12 |
| Q3 2025 | 1 | $0.40 | $0.43 | $0.42 |
| Q4 2025 | 1 | $0.09 | $0.09 | $0.09 |
| Q1 2026 | 1 | -$0.05 | -$0.05 | -$0.05 |
| Q2 2026 | 1 | $0.02 | $0.03 | $0.02 |
| Q3 2026 | 1 | $0.17 | $0.18 | $0.18 |
| Q4 2026 | 1 | $0.27 | $0.29 | $0.29 |
| Q1 2027 | 1 | $0.22 | $0.23 | $0.23 |
| Q2 2027 | 1 | $0.45 | $0.48 | $0.47 |
| Q3 2027 | 1 | $0.62 | $0.67 | $0.65 |
| Q4 2027 | 1 | $0.61 | $0.66 | $0.65 |
| Q1 2028 | 1 | $0.19 | $0.21 | $0.20 |
| Q2 2028 | 1 | $0.53 | $0.57 | $0.56 |
| Q3 2028 | 1 | $0.61 | $0.66 | $0.64 |
| Q4 2028 | 1 | $0.48 | $0.52 | $0.51 |
GeneDx Holdings Corp. Earnings Date And Information
GeneDx Holdings Corp. last posted its earnings results on Tuesday, October 28th, 2025. The company reported $-0.26513 earnings per share for the quarter, missing analysts' consensus estimates of $0.4229 by $0.68803. The company had revenue of 116.74 M for the quarter and had revenue of 305.45 M for the year. GeneDx Holdings Corp. has generated $-2 earnings per share over the last year ($-1.94 diluted earnings per share) and currently has a price-to-earnings ratio of 2211.26. GeneDx Holdings Corp. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 17th, 2025 based on prior year's report dates.
GeneDx Holdings Corp. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/28/2025 | Q3 2025 | $0.42 | -$0.27 | -0.69 | $104.62 M | $116.74 M |
| 07/29/2025 | Q2 2025 | $0.12 | $0.38 | 0.26 | $85.45 M | $102.69 M |
| 04/30/2025 | Q1 2025 | $0.06 | -$0.23 | -0.29 | N/A | $87.12 M |
| 02/20/2025 | Q4 2024 | N/A | $0.20 | N/A | N/A | $95.64 M |
| 10/29/2024 | Q3 2024 | N/A | -$0.31 | N/A | $64.98 M | $76.87 M |
| 07/30/2024 | Q2 2024 | N/A | -$1.10 | N/A | $59.31 M | $70.51 M |
| 03/29/2024 | Q1 2024 | N/A | -$0.78 | N/A | N/A | $62.42 M |
| 12/29/2023 | Q4 2023 | N/A | -$0.99 | N/A | N/A | $57.42 M |
| 09/30/2023 | Q3 2023 | N/A | -$1.64 | N/A | $52.42 M | $53.30 M |
| 06/30/2023 | Q2 2023 | N/A | -$1.84 | N/A | $47.59 M | $48.71 M |
| 03/31/2023 | Q1 2023 | N/A | -$3.04 | N/A | N/A | $43.14 M |
| 03/16/2023 | Q4 2022 | N/A | -$26.23 | N/A | N/A | $61.35 M |
| 11/14/2022 | Q3 2022 | N/A | -$6.72 | N/A | N/A | $83.23 M |
| 08/15/2022 | Q2 2022 | N/A | -$8.38 | N/A | N/A | $36.17 M |
| 05/12/2022 | Q1 2022 | N/A | -$8.71 | N/A | N/A | $53.94 M |
| 03/14/2022 | Q4 2021 | N/A | -$5.49 | N/A | N/A | $57.80 M |
| 11/15/2021 | Q3 2021 | N/A | $5.58 | N/A | N/A | $43.18 M |
| 07/21/2021 | Q2 2021 | N/A | -$27.05 | N/A | N/A | $47.02 M |
| 03/30/2021 | Q1 2021 | N/A | -$114.35 | N/A | N/A | $64.20 M |
| 12/30/2020 | Q4 2020 | N/A | -$74.94 | N/A | N/A | $63.96 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
GeneDx Holdings Corp. Earnings: FAQ's
GeneDx Holdings Corp. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 17th, 2025 based offlast year's report dates.
The conference call for GeneDx Holdings Corp.'s latest earnings report can be listened to online.
The conference call transcript for GeneDx Holdings Corp.'s latest earnings report can be read online.
GeneDx Holdings Corp. (:WGSWW) has a recorded annual revenue of $305.45 M.
GeneDx Holdings Corp. (:WGSWW) has a recorded net income of $-52,286,000.GeneDx Holdings Corp. has generated $-1.94 earnings per share over the last four quarters.
GeneDx Holdings Corp. (:WGSWW) has a price-to-earnings ratio of 2211.26 and price/earnings-to-growth ratio is 22.11.